T. Rowe Price Associates’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $90.9M | Buy |
1,114,516
+639,368
| +135% | +$46.2M | 0.01% | 721 |
|
|
2026
Q1 | $32.4M | Buy |
475,148
+15,034
| +3% | +$1.06M | ﹤0.01% | 904 |
|
|
2025
Q4 | $35M | Buy |
460,114
+1,784
| +0.4% | +$130K | ﹤0.01% | 919 |
|
|
2025
Q3 | $28.1M | Buy |
458,330
+4,728
| +1% | +$246K | ﹤0.01% | 970 |
|
|
2025
Q2 | $22.2M | Sell |
453,602
-14,952
| -3% | -$710K | ﹤0.01% | 941 |
|
|
2025
Q1 | $23.9M | Sell |
468,554
-40,650
| -8% | -$2.03M | ﹤0.01% | 911 |
|
|
2024
Q4 | $23M | Sell |
509,204
-50,542
| -9% | -$2.16M | ﹤0.01% | 964 |
|
|
2024
Q3 | $20.8M | Sell |
559,746
-46,930
| -8% | -$1.57M | ﹤0.01% | 984 |
|
|
2024
Q2 | $18.6M | Sell |
606,676
-33,191
| -5% | -$1.08M | ﹤0.01% | 979 |
|
|
2024
Q1 | $18.6M | Sell |
639,867
-358,436
| -36% | -$10M | ﹤0.01% | 990 |
|
|
2023
Q4 | $27.5M | Sell |
998,303
-104,142
| -9% | -$2.38M | ﹤0.01% | 868 |
|
|
2023
Q3 | $24.7M | Sell |
1,102,445
-974,489
| -47% | -$36.2M | ﹤0.01% | 872 |
|
|
2023
Q2 | $84.5M | Buy |
2,076,934
+359,169
| +21% | +$17.6M | 0.01% | 564 |
|
|
2023
Q1 | $83.2M | Buy |
1,717,765
+433,376
| +34% | +$19.8M | 0.01% | 552 |
|
|
2022
Q4 | $49M | Sell |
1,284,389
-182,804
| -12% | -$7.6M | 0.01% | 665 |
|
|
2022
Q3 | $73.7M | Sell |
1,467,193
-173,793
| -11% | -$8.52M | 0.01% | 549 |
|
|
2022
Q2 | $65.7M | Sell |
1,640,986
-77,472
| -5% | -$2.72M | 0.01% | 793 |
|
|
2022
Q1 | $64.1M | Sell |
1,718,458
-388,103
| -18% | -$15M | 0.01% | 885 |
|
|
2021
Q4 | $83.9M | Buy |
2,106,561
+1,501
| +0.1% | +$57.5K | 0.01% | 821 |
|
|
2021
Q3 | $78.3M | Sell |
2,105,060
-7,608
| -0.4% | -$313K | 0.01% | 848 |
|
|
2021
Q2 | $89.3M | Sell |
2,112,668
-44,206
| -2% | -$1.89M | 0.01% | 829 |
|
|
2021
Q1 | $102M | Sell |
2,156,874
-58,143
| -3% | -$3.45M | 0.01% | 773 |
|
|
2020
Q4 | $135M | Sell |
2,215,017
-54,500
| -2% | -$3.21M | 0.01% | 627 |
|
|
2020
Q3 | $106M | Sell |
2,269,517
-188,909
| -8% | -$9.3M | 0.01% | 639 |
|
|
2020
Q2 | $125M | Buy |
2,458,426
+405,589
| +20% | +$19.9M | 0.02% | 573 |
|
|
2020
Q1 | $91.6M | Sell |
2,052,837
-1,985,150
| -49% | -$99.9M | 0.01% | 596 |
|
|
2019
Q4 | $194M | Buy |
4,037,987
+288,469
| +8% | +$12.3M | 0.03% | 486 |
|
|
2019
Q3 | $127M | Sell |
3,749,518
-117,771
| -3% | -$5.13M | 0.02% | 553 |
|
|
2019
Q2 | $174M | Buy |
3,867,289
+342,747
| +10% | +$13.5M | 0.02% | 499 |
|
|
2019
Q1 | $133M | Buy |
3,524,542
+772,296
| +28% | +$25.9M | 0.02% | 565 |
|
|
2018
Q4 | $94.5M | Buy |
2,752,246
+259,461
| +10% | +$9.33M | 0.02% | 625 |
|
|
2018
Q3 | $117M | Buy |
2,492,785
+1,824,417
| +273% | +$75.5M | 0.02% | 619 |
|
|
2018
Q2 | $22.5M | Buy |
+668,368
| New | +$20.8M | ﹤0.01% | 1165 |
|
|
2016
Q1 | – | Sell |
-8,390
| Closed | -$272K | – | 2525 |
|
|
2015
Q4 | $272K | Buy |
+8,390
| New | +$247K | ﹤0.01% | 2194 |
|
Other funds holding PTCT
RI
JT
T. Rowe Price Associates's PTCT Position: Q2 2026 in Review
T. Rowe Price Associates increased its PTC Therapeutics (PTCT) stake by 135% in Q2 2026, buying an estimated $46.2M and bringing the position to 1,114,516 shares worth $90.9M. The position accounts for 0.01% of the portfolio, ranked #721.
T. Rowe Price Associates first reported a position in PTCT in Q4 2015 and has held it in 34 quarters since. The position peaked at $194M in Q4 2019. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- T. Rowe Price Associates held 1,114,516 shares of PTC Therapeutics worth $90.9M as of Q2 2026.
- T. Rowe Price Associates bought 639,368 PTC Therapeutics shares in Q2 2026, an estimated $46.2M.
- PTC Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #721 holding.
- T. Rowe Price Associates first reported a position in PTC Therapeutics in Q4 2015 and has held it in 34 quarters since.
- T. Rowe Price Associates's PTC Therapeutics position peaked at $194M in Q4 2019.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.